EGFR and non-small cell lung carcinoma: In our other study [55], compound BTT-5 (Figure 3) was determined to possess anti-NSCLC (IC50 = 9.51 μM) activity and selective EGFR inhibitory (58.32%) effects at a 10 μM concentration.